Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

4.82
-0.0400-0.82%
Pre-market: 4.890.0700+1.45%07:24 EDT
Volume:78.82K
Turnover:375.59K
Market Cap:82.80M
PE:-2.77
High:4.99
Open:4.90
Low:4.64
Close:4.86
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:0.66
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7400
EPS(LYR):-1.6791
ROE:-240.35%
ROA:-43.98%
PB:19.22
PE(LYR):-2.87

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ)

TIPRANKS
·
Apr 16

Verrica late-breaking Phase 2 VP-315 data suggests abscopal effect in basal cell carcinoma

Reuters
·
Apr 10

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of Vp-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

THOMSON REUTERS
·
Apr 10

Verrica Pharma CEO to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)

TIPRANKS
·
Mar 12

Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand

Reuters
·
Mar 11

Verrica FY 2025 total revenue rose 370% to USD 35.58 million as net loss narrowed 77% to USD 17.89 million

Reuters
·
Mar 11

Verrica Pharmaceuticals Q4 Adj. EPS $(0.51) Beats $(0.79) Estimate, Sales $5.092M Beat $4.525M Estimate

Benzinga Earnings
·
Mar 11

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals: Co Advancing Vp-315 Toward Phase 3 Program for Basal Cell Carcinoma in 2026

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals: Co Expects to Initiate Second Phase 3 Study of Ycanth in US, Japan With Torii Pharmaceutical in Mid-2026

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Adjusted Net Income USD -7.2 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Net Income USD -8.074 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Income From Operations USD -7.192 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Reuters
·
Mar 07

Verrica Pharmaceuticals Inc. to Report Q4 and Full-Year Financial Results and Provide Corporate Update

Reuters
·
Mar 05

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

THOMSON REUTERS
·
Mar 05